Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.

Rawan G Faramand Sae Bom Lee Michael D Jain Biwei Cao Xuefeng Wang Marion Subklewe Marion Subklewe Johannes F Fahrmann Neeraj Y Saini Samir M Hanash Yun Pyo Kang Darwin Chang Paulo C Rodriguez Erin A Dean Taiga Nishihori Bijal D Shah Aleksander Lazaryan Julio C Chavez Farhad Khimani Javier A Pinilla-Ibarz Marian Dam Kayla M Reid Salvatore A Corallo Meghan Menges Melanie Hidalgo Vargas Jessica K Mandula Brian A Holliday Christina A Bachmeier Kelly A Speth Qinghua Song Mike Mattie Frederick L Locke Marco L Davila

Published in: Blood cancer discovery (2024)

CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a simple clinically applicable model using pre-lymphodepletion CRP and ferritin can identify patients at high risk of poor outcomes. This article is featured in Selected Articles from This Issue, p. 80.

Keyphrases